<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="57098">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01986933</url>
  </required_header>
  <id_info>
    <org_study_id>CIM003JG</org_study_id>
    <nct_id>NCT01986933</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study of CIM331 for Atopic Dermatitis Patients</brief_title>
  <official_title>A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF CIM331 IN ATOPIC DERMATITIS PATIENTS WHO ARE INADEQUATELY CONTROLLED BY OR INTOLERANT TO TOPICAL THERAPY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chugai Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chugai Pharmaceutical</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>Germany: Paul-Ehrlich-Institu</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety, tolerability and efficacy of CIM331, compared to placebo, in atopic
      dermatitis patients who are inadequately controlled by or intolerant to topical therapy
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percent improvement from baseline in pruritus Visual Analogue Scale (VAS)</measure>
    <time_frame>baseline to week12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent improvement from baseline in pruritus VAS at week12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement from baseline in Eczema Area and Severity Index (EASI)</measure>
    <time_frame>baseline to week12 (Part A), up to week64 (Part B)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement from baseline in SCORing Atopic Dermatitis (SCORAD)</measure>
    <time_frame>baseline to week12 (Part A), up to week64 (Part B)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement from baseline in static Investigator's Global Assessment (sIGA)</measure>
    <time_frame>baseline to week12 (Part A), up to week64 (Part B)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement from baseline in Body Surface Area (BSA) of AD involvement</measure>
    <time_frame>baseline to week12 (Part A), up to week64 (Part B)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Group1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PartA:CIM331 Part B:CIM331</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PartA:CIM331 Part B:CIM331</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PartA:CIM331 Part B:CIM331</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PartA:CIM331 Part B:CIM331</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PartA:Placebo Part B:CIM331</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CIM331</intervention_name>
    <arm_group_label>Group1</arm_group_label>
    <arm_group_label>Group2</arm_group_label>
    <arm_group_label>Group3</arm_group_label>
    <arm_group_label>Group4</arm_group_label>
    <arm_group_label>Group5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Group5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥18 and ≤65 years of age at the time of consent.

          -  Patients with Atopic Dermatitis

          -  Pruritus visual analogue scale (VAS) ≥50 mm at the screening and baseline visit

          -  Eczema Area and Severity Index (EASI) ≥10 at the screening and baseline visit

          -  static Investigator's Global Assessment (sIGA) score ≥3 at the baseline visit

        Exclusion Criteria:

          -  Serological evidence of hepatitis B virus or hepatitis C virus infection

          -  Known human immunodeficiency virus infection

          -  Ongoing treatment with specific or non-specific hyposensitization therapy for AD

          -  Treatment with mild or moderately potent topical corticosteroids (TCS) within 1 week
             prior to randomization

          -  History of infection including skin infection requiring treatment with oral or
             intravenous (IV) antibiotics, antivirals, or antifungals within 1 week prior to
             randomization.

          -  Evidence of tuberculosis (TB) infection as defined by a positive purified protein
             derivative (PPD) and/or positive interferon-gamma release assay.

          -  Pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michiaki Tanaka</last_name>
    <role>Study Director</role>
    <affiliation>Chugai Pharmaceutical</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <email>cim331@chugai-pharm.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 27, 2014</lastchanged_date>
  <firstreceived_date>October 31, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
